Tag: ADCs

Antibody drug conjugates (ADCs) are an upcoming class of targeted therapeutic agents that have garnered the attention of pharmaceutical companies, and academic / research institutions across the world. Fundamentally, these complex biotherapeutic entities represent the combination of the target specificity of an antibody and the therapeutic features of a chemotherapy / cytotoxic drug. Such conjugates

Over the years, various technological advancements, such as antibody engineering for site-specific conjugation and enhanced pharmacokinetic and pharmacodynamic properties, have paved the way for antibody drug conjugates (ADCs) to be recognized as potent therapies targeting a wide range of indications, including solid tumors and hematological malignancies. ADC Therapeutics are engineered therapies comprised of monoclonal antibodies

Antibody drug conjugates (ADCs) have captured the attention of both large and small pharmaceutical companies, and academic / research institutions, for more than a decade. For the past few years, several failures of clinical trials were blamed for the lack of interest of some companies in this therapeutic approach. However, after a decade-long dribble of

So, another round of the World ADCs just concluded. With a stellar line up that included Alain Beck from Pierre Fabre, Thorsten Sperber from Immunomedics, Nicholas Choong form Seattle Genetics, Rakesh Dixit from BioNavigen, Trevor Hallam from Sutro Bio and many other eminent personalities, the event did live up to its expectations. ADCs continue to

For more insights about the market, please click here.